<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00961636</url>
  </required_header>
  <id_info>
    <org_study_id>0524A-102</org_study_id>
    <secondary_id>2009_634</secondary_id>
    <nct_id>NCT00961636</nct_id>
  </id_info>
  <brief_title>A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)</brief_title>
  <official_title>A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of ERN/LRPT in Patients With Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy of laropiprant (LRPT) to reduce flushing symptoms
      beyond 6 months and will measure the impact of withdrawal of laropiprant in patients
      following 20 weeks of stable maintenance therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number Participants With Days Per Week With Global Flushing Severity Score (GFSS) ≥4 Partitioned Into 6 Categories During the Postwithdrawal Period</measure>
    <time_frame>Week 21 to Week 32</time_frame>
    <description>Flushing symptoms were recorded using participant's response to the Global Flushing Severity Score (GFSS), which assessed the overall severity of the flushing experience, using a scale of 0 (no symptom) to 10 (extreme). The number of days/week was derived as: 7*(total number of days with GFSS ≥4 across Weeks 21-32 divided by the total number of days with nonmissing GFSS across the same period). The number of days/week with a GFSS ≥4 for each participant was listed in 1 of the following 6 categories: 0, &gt;0 to 0.5, &gt;0.5 to 1, &gt;1 to 2, &gt;2 to 3, and &gt;3 days per week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Maximum GFSS ≥4 During the Post-withdrawal Period</measure>
    <time_frame>Week 21 to Week 32</time_frame>
    <description>Flushing symptoms were recorded using participant's response to the Global Flushing Severity Score (GFSS), which assesses the overall severity of the flushing experience (including redness, warmth, tingling, or itching) using a scale with response categories of None, Mild, Moderate, Severe, and Extreme. The categories were supplemented with numbers 0 to 10 to allow for greater precision within each category (None=0, Mild=1-3, Moderate=4-6, Severe=7-9, Extreme=10). The daily response was recorded in the morning, and reflected the symptoms experienced during the previous 24 hours.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1152</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>ERN/LRPT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg
tablets daily (2g/40 mg total) for 28 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ERN/LRPT then ERN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks then Two 1g tablets ERN (2g total) once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ER niacin (+) laropiprant (ERN/LRPT)</intervention_name>
    <description>One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks</description>
    <arm_group_label>ERN/LRPT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ER niacin (+) laropiprant (ERN/LRPT)</intervention_name>
    <description>One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks.</description>
    <arm_group_label>ERN/LRPT then ERN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extended-release niacin (ERN)</intervention_name>
    <description>Two 1g tablets ERN (2g total) once daily for 12 weeks.</description>
    <arm_group_label>ERN/LRPT then ERN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to ERN/LRPT</intervention_name>
    <description>One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is a male, or a female who is unlikely to conceive, as indicated by meeting at
             least one of the following conditions: (a) Patient is a male.(b) Patient is a female
             of reproductive potential and either agrees to remain abstinent (if this form of birth
             control is accepted by local regulatory agencies and review committees as the sole
             method of birth control) or use (or have their partner use) 2 acceptable methods of
             birth control within the projected duration of the study.(c) Patient is a female who
             is not of reproductive potential and therefore eligible to participate in this study
             without requiring the use of contraception.

          -  Lipid-modifying therapy (LMT) is appropriate for the patient

          -  Patient meets one of the following criteria based on the National Cholesterol
             Education Program Adult Treatment Panel III guidelines : 1) High risk and is on a
             statin with LDL-cholesterol (LDL-C) &lt;100 mg/dL or intolerant to statins with LDL-C
             &lt;120 mg/dL; 2) Multiple risk with LDL-C &lt;130 mg/dL; 3) Low risk with LDL-C &lt;190 mg/dL

          -  Patient has triglyceride levels &lt;500 mg/dL

        Exclusion Criteria:

          -  Patient is pregnant, breast-feeding, or expecting to conceive

          -  Patient has a history of cancer within 5 years of screening (except certain skin and
             cervical cancers)

          -  Female patient plans to donate eggs during the study

          -  Male patient plans to donate sperm during the study

          -  Patient has or has a history of any condition, therapy, or lab abnormality that might
             confound the study results, interfere with participation for the full duration of the
             study, or make participation in the study not in the patient's best interest

          -  Patient has donated or received blood within 8 weeks of screening or plans to
             donate/receive blood during and 8 weeks after the study

          -  Patient is experiencing menopausal hot flashes

          -  Patient has chronic heart failure, uncontrolled cardiac arrhythmias, or poorly
             controlled hypertension

          -  Patient has type 1 or 2 diabetes and is poorly-controlled, newly diagnosed, has
             recently had repeated hypoglycemia, or is taking new or recently adjusted antidiabetic
             medication

          -  Patient has uncontrolled metabolic or endocrine disease that influences serum lipids
             or lipoproteins

          -  Patient has kidney disease

          -  Patient had active peptic ulcers within 3 months of screening

          -  Patient has a history of heart attack, stroke, heart bypass surgery, angina, or
             angioplasty within 3 months of screening

          -  Patient is human immunodeficiency virus (HIV) positive

          -  Patient is taking or has taken niacin &gt;50 mg daily within 6 weeks of screening

          -  Patient has had a change to type or dose of LMT regimen within 6 weeks of Visit 1

          -  Patient is taking a statin and a fibrate at screening

          -  Patient is taking a long acting non-steroidal anti-inflammatory drug (NSAID), such as
             naproxen or aspirin &gt;100 mg per day at screening

          -  Patient has arterial bleeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Israel</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Panama</country>
    <country>Peru</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Maccubbin DL, Chen F, Anderson JW, Sirah W, McCrary Sisk C, Kher U, Olsson AG, Bays HE, Mitchel YB. Effectiveness and safety of laropiprant on niacin-induced flushing. Am J Cardiol. 2012 Sep 15;110(6):817-22. doi: 10.1016/j.amjcard.2012.05.009. Epub 2012 Jun 8.</citation>
    <PMID>22683042</PMID>
  </results_reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2009</study_first_submitted>
  <study_first_submitted_qc>August 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2009</study_first_posted>
  <results_first_submitted>January 14, 2012</results_first_submitted>
  <results_first_submitted_qc>January 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 17, 2012</results_first_posted>
  <last_update_submitted>January 29, 2015</last_update_submitted>
  <last_update_submitted_qc>January 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ERN/LRPT</title>
          <description>One 1g/20 mg tablet Extended -release niacin (+) laropiprant (ERN/LRPT) once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks</description>
        </group>
        <group group_id="P2">
          <title>ERN/LRPT Then ERN</title>
          <description>One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks then Two 1g tablets ERN (2g total) once daily for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="463"/>
                <participants group_id="P2" count="456"/>
                <participants group_id="P3" count="233"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="356"/>
                <participants group_id="P2" count="325"/>
                <participants group_id="P3" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="131"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Flushing Symptoms</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ERN/LRPT</title>
          <description>One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks</description>
        </group>
        <group group_id="B2">
          <title>ERN/LRPT Then ERN</title>
          <description>One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks then Two 1g tablets ERN (2g total) once daily for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="463"/>
            <count group_id="B2" value="456"/>
            <count group_id="B3" value="233"/>
            <count group_id="B4" value="1152"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="334"/>
                    <measurement group_id="B2" value="328"/>
                    <measurement group_id="B3" value="166"/>
                    <measurement group_id="B4" value="828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="184"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="279"/>
                    <measurement group_id="B2" value="312"/>
                    <measurement group_id="B3" value="146"/>
                    <measurement group_id="B4" value="737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number Participants With Days Per Week With Global Flushing Severity Score (GFSS) ≥4 Partitioned Into 6 Categories During the Postwithdrawal Period</title>
        <description>Flushing symptoms were recorded using participant's response to the Global Flushing Severity Score (GFSS), which assessed the overall severity of the flushing experience, using a scale of 0 (no symptom) to 10 (extreme). The number of days/week was derived as: 7*(total number of days with GFSS ≥4 across Weeks 21-32 divided by the total number of days with nonmissing GFSS across the same period). The number of days/week with a GFSS ≥4 for each participant was listed in 1 of the following 6 categories: 0, &gt;0 to 0.5, &gt;0.5 to 1, &gt;1 to 2, &gt;2 to 3, and &gt;3 days per week.</description>
        <time_frame>Week 21 to Week 32</time_frame>
        <population>Analysis performed using the Full Analysis Set (FAS) population which included all randomized participants that did not have a withdrawal visit and/or did not have at least 1 GFSS score during the post-withdrawal period (Weeks 21 to 32).</population>
        <group_list>
          <group group_id="O1">
            <title>ERN/LRPT</title>
            <description>One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks</description>
          </group>
          <group group_id="O2">
            <title>ERN/LRPT Then ERN</title>
            <description>One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks then Two 1g tablets ERN (2g total) once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number Participants With Days Per Week With Global Flushing Severity Score (GFSS) ≥4 Partitioned Into 6 Categories During the Postwithdrawal Period</title>
          <description>Flushing symptoms were recorded using participant's response to the Global Flushing Severity Score (GFSS), which assessed the overall severity of the flushing experience, using a scale of 0 (no symptom) to 10 (extreme). The number of days/week was derived as: 7*(total number of days with GFSS ≥4 across Weeks 21-32 divided by the total number of days with nonmissing GFSS across the same period). The number of days/week with a GFSS ≥4 for each participant was listed in 1 of the following 6 categories: 0, &gt;0 to 0.5, &gt;0.5 to 1, &gt;1 to 2, &gt;2 to 3, and &gt;3 days per week.</description>
          <population>Analysis performed using the Full Analysis Set (FAS) population which included all randomized participants that did not have a withdrawal visit and/or did not have at least 1 GFSS score during the post-withdrawal period (Weeks 21 to 32).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="354"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0 Days per week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291"/>
                    <measurement group_id="O2" value="181"/>
                    <measurement group_id="O3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;0 to ≤ 0.5 Days per week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;0.5 to ≤1 Days per week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;1.0 to ≤2 Days per week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;2 to ≤3 Days per week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;3 Days per week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The closed ordered testing procedure was applied to the efficacy hypotheses. If statistical significance was achieved for the primary hypothesis, then the secondary hypothesis was tested. All tests were performed at significance level 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel (CMH) test was stratified by country</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Maximum GFSS ≥4 During the Post-withdrawal Period</title>
        <description>Flushing symptoms were recorded using participant's response to the Global Flushing Severity Score (GFSS), which assesses the overall severity of the flushing experience (including redness, warmth, tingling, or itching) using a scale with response categories of None, Mild, Moderate, Severe, and Extreme. The categories were supplemented with numbers 0 to 10 to allow for greater precision within each category (None=0, Mild=1-3, Moderate=4-6, Severe=7-9, Extreme=10). The daily response was recorded in the morning, and reflected the symptoms experienced during the previous 24 hours.</description>
        <time_frame>Week 21 to Week 32</time_frame>
        <population>Analysis performed using the Full Analysis Set (FAS) population which included all randomized participants that did not have a withdrawal visit and/or did not have at least 1 GFSS score during the post-withdrawal period (Weeks 21 to 32).</population>
        <group_list>
          <group group_id="O1">
            <title>ERN/LRPT</title>
            <description>One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks</description>
          </group>
          <group group_id="O2">
            <title>ERN/LRPT Then ERN</title>
            <description>One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks then Two 1g tablets ERN (2g total) once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Maximum GFSS ≥4 During the Post-withdrawal Period</title>
          <description>Flushing symptoms were recorded using participant's response to the Global Flushing Severity Score (GFSS), which assesses the overall severity of the flushing experience (including redness, warmth, tingling, or itching) using a scale with response categories of None, Mild, Moderate, Severe, and Extreme. The categories were supplemented with numbers 0 to 10 to allow for greater precision within each category (None=0, Mild=1-3, Moderate=4-6, Severe=7-9, Extreme=10). The daily response was recorded in the morning, and reflected the symptoms experienced during the previous 24 hours.</description>
          <population>Analysis performed using the Full Analysis Set (FAS) population which included all randomized participants that did not have a withdrawal visit and/or did not have at least 1 GFSS score during the post-withdrawal period (Weeks 21 to 32).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="362"/>
                <count group_id="O2" value="354"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="173"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The closed ordered testing procedure was applied to the efficacy hypotheses. If statistical significance was achieved for the primary hypothesis, then the secondary hypothesis was tested. All tests were performed at significance level 0.05.</p_value_desc>
            <method>Unconditional Miettinen and Nurminen</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Of 1152 randomized participants, 1148 participants took at least one dose of study medication and were included in the analyses of safety.</desc>
      <group_list>
        <group group_id="E1">
          <title>ERN/LRPT</title>
          <description>One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks</description>
        </group>
        <group group_id="E2">
          <title>ERN/LRPT Then ERN</title>
          <description>One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks then Two 1g tablets ERN (2g total) once daily for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="461"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Intraocular melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="461"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Tongue cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Epileptic aura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="455"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="461"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="455"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="461"/>
                <counts group_id="E2" subjects_affected="162" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="40" subjects_affected="33" subjects_at_risk="461"/>
                <counts group_id="E2" events="35" subjects_affected="34" subjects_at_risk="455"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="53" subjects_affected="23" subjects_at_risk="461"/>
                <counts group_id="E2" events="65" subjects_affected="28" subjects_at_risk="455"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="67" subjects_affected="51" subjects_at_risk="461"/>
                <counts group_id="E2" events="116" subjects_affected="66" subjects_at_risk="455"/>
                <counts group_id="E3" events="18" subjects_affected="17" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="77" subjects_affected="52" subjects_at_risk="461"/>
                <counts group_id="E2" events="130" subjects_affected="85" subjects_at_risk="455"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publications derived from this study should include input from the investigator(s) and Sponsor personnel. Subsequent to the multicenter publication, or 24 months after completion of the study, whichever comes first, an investigator and/or his/her colleagues may publish the results for their study site independently. The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

